T. Rowe Price Associates’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

T. Rowe Price Associates’s Portfolio IRLA Stock Details IRLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-123	Closed	-$55K	–	3028
2022 Q2	$55K	Buy	123 +51	+71%	+$36K	﹤0.01%	2845
2022 Q1	$89K	Sell	72 -7	-9%	-$9.53K	﹤0.01%	2868
2021 Q4	$201K	Sell	79 -394	-83%	-$2.4M	﹤0.01%	2760
2021 Q3	$8.67M	Buy	473 +276	+140%	+$4.39M	﹤0.01%	1434
2021 Q2	$2.09M	Buy	+197	New	+$1.65M	﹤0.01%	1722
2020 Q3	–	Sell	-386	Closed	-$3.57M	–	2618
2020 Q2	$3.57M	Sell	386 -31	-7%	-$284K	﹤0.01%	1427
2020 Q1	$3.8M	Sell	417 -69	-14%	-$681K	﹤0.01%	1377
2019 Q4	$5.46M	Buy	+486	New	+$2.93M	﹤0.01%	1385

Other funds holding IRLA

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PHAM

Pacific Heights Asset Management San Francisco, California $3.16B AUM 42.38% 1-Year Est. Return

T. Rowe Price Associates's IRLA Position: Q3 2022 in Review

T. Rowe Price Associates sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q3 2022, closing a stake of 123 shares — an estimated $55K sold.

T. Rowe Price Associates first reported a position in IRLA in Q4 2019 and held it in 8 quarters. The position peaked at $8.67M in Q3 2021. 58 funds tracked by Wall St. Rank hold IRLA as of Q3 2022.

T. Rowe Price Associates reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
T. Rowe Price Associates sold 123 IRulya Therapeutics Inc. Common Stock shares in Q3 2022, an estimated $55K.
T. Rowe Price Associates first reported a position in IRulya Therapeutics Inc. Common Stock in Q4 2019 and held it in 8 quarters.
T. Rowe Price Associates's IRulya Therapeutics Inc. Common Stock position peaked at $8.67M in Q3 2021.
58 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q3 2022.

Based on T. Rowe Price Associates's 13F filing for Q3 2022, filed 14 Nov 2022.